Alafi Capital Company

Incision is a developer of a medical education platform designed to provide a standardized approach to performing medical procedures through a series of practical steps and sub-steps. The platform facilitates access to shared experiences, skills, and expertise, enabling medical students to achieve rapid and thorough preparation for their roles in the operating room. By focusing on the development of essential competencies and skills, Incision aims to enhance the training of future healthcare professionals.

Resolve BioSciences GmbH, founded in 2016 and based in Monheim am Rhein, Germany, specializes in spatial multiomics analysis platforms that enhance the understanding of single-cell spatial biology. The company's innovative technology enables researchers to obtain high-resolution spatial views of subcellular gene expression activities. Resolve BioSciences offers a range of services that encompass bioinformatics, imaging, genomics, transcriptomics, histology, and pathology, among others. Their expertise extends to various fields, including neuroscience, oncology, infectious diseases, and agrigenomics, facilitating advanced studies in cell atlasing and single-cell analysis.

Resolve BioSciences GmbH, founded in 2016 and based in Monheim am Rhein, Germany, specializes in spatial multiomics analysis platforms that enhance the understanding of single-cell spatial biology. The company's innovative technology enables researchers to obtain high-resolution spatial views of subcellular gene expression activities. Resolve BioSciences offers a range of services that encompass bioinformatics, imaging, genomics, transcriptomics, histology, and pathology, among others. Their expertise extends to various fields, including neuroscience, oncology, infectious diseases, and agrigenomics, facilitating advanced studies in cell atlasing and single-cell analysis.

Bolt Threads Inc. is a materials company based in Emeryville, California, founded in 2009. Originally named Refactored Materials, Inc., the company specializes in the manufacture of innovative fibers and fabrics, particularly biofabricated silk fibers known as Microsilk™, which are derived from natural proteins and produced through proprietary technology and bioengineering. Bolt Threads focuses on developing sustainable textile materials for various industries, including apparel, footwear, and beauty brands. Its approach combines biology and fermentation with traditional textile production methods, enabling the transformation of textile waste into high-quality products. Through its cutting-edge technology, Bolt Threads aims to advance the performance and design of textiles while promoting environmental sustainability.

Assurex Health is a personalized medicine company based in Mason, Ohio, that specializes in pharmacogenomics. The company is dedicated to assisting healthcare providers in identifying the most suitable medications for individual patients with various medical conditions, including neuropsychiatric disorders and chronic pain. By offering treatment decision support, Assurex Health empowers clinicians to collect and analyze genetic information, thereby enhancing the precision of medication selection tailored to each patient's unique genetic makeup.

Bolt Threads Inc. is a materials company based in Emeryville, California, founded in 2009. Originally named Refactored Materials, Inc., the company specializes in the manufacture of innovative fibers and fabrics, particularly biofabricated silk fibers known as Microsilk™, which are derived from natural proteins and produced through proprietary technology and bioengineering. Bolt Threads focuses on developing sustainable textile materials for various industries, including apparel, footwear, and beauty brands. Its approach combines biology and fermentation with traditional textile production methods, enabling the transformation of textile waste into high-quality products. Through its cutting-edge technology, Bolt Threads aims to advance the performance and design of textiles while promoting environmental sustainability.

Kreatech Diagnostics is a molecular diagnostics company that specializes in the development and commercialization of advanced detection products for the life sciences and healthcare sectors. The company is known for its innovative Fluorescent in Situ Hybridization (FISH) probes, which are essential tools for diagnostic and research applications. In addition to FISH probes, Kreatech offers a range of products for microarray labeling, utilizing its proprietary non-enzymatic Universal Linkage System labeling technology. This focus on cutting-edge detection solutions positions Kreatech as a key player in the molecular diagnostics field.

Kreatech Diagnostics is a molecular diagnostics company that specializes in the development and commercialization of advanced detection products for the life sciences and healthcare sectors. The company is known for its innovative Fluorescent in Situ Hybridization (FISH) probes, which are essential tools for diagnostic and research applications. In addition to FISH probes, Kreatech offers a range of products for microarray labeling, utilizing its proprietary non-enzymatic Universal Linkage System labeling technology. This focus on cutting-edge detection solutions positions Kreatech as a key player in the molecular diagnostics field.

Arcxis Biotechnologies specializes in creating innovative solutions for molecular diagnostic challenges. The company develops proprietary microfluidics and advanced detection methods, along with streamlined sample preparation and comprehensive automation technology. Its goal is to enhance the reliability, robustness, and accessibility of molecular methods, thereby improving diagnostic processes in various applications.

Natera, Inc. is a diagnostic and research company specializing in genetic testing services, particularly in the areas of preconception and prenatal diagnostics. Founded in 2003 and headquartered in San Carlos, California, Natera offers a range of products including the Panorama non-invasive prenatal test, which screens for chromosomal abnormalities in fetuses, and Vistara, a test for single-gene mutations. Additionally, the company provides Horizon carrier screening to assess carrier status for various genetic diseases, and Spectrum, which analyzes genetic conditions during in vitro fertilization. Natera's Anora product analyzes fetal chromosomes to understand miscarriage causes, while its non-invasive paternity tests determine parentage through fetal DNA analysis. The company's Signatera technology focuses on circulating tumor DNA to monitor cancer recurrence. Natera distributes its products through a direct sales force and a network of approximately 100 laboratory and distribution partners, both domestically and internationally. The company collaborates with BGI Genomics to develop genetic testing assays and has partnered with Foundation Medicine for personalized cancer monitoring assays.

ISTO Technologies, Inc., an orthobiologics company, develops biologic products to regenerate and restore function to damaged cartilage and bone. It offers InQu, a resorbable bone graft extender and substitute; NuQu, a cell-based injectable therapy for disc regeneration; and DeNovo ET, an engineered cartilage implant for the repair and regeneration of knee cartilage. The company provides its products through distributors. ISTO Technologies, Inc. was founded in 1997 and is based in St. Louis, Missouri.

Stereotaxis, Inc. specializes in the design, manufacture, and marketing of robotic magnetic navigation systems aimed at enhancing the treatment of arrhythmias and coronary artery disease. Its core products include the Genesis and Niobe systems, which facilitate complex interventional procedures by enabling image-guided catheter and guidewire navigation within the heart. The company also offers the Vdrive system, which provides stability for diagnostic and therapeutic devices, and the Odyssey solution, a real-time information management system for interventional labs. Additionally, Stereotaxis produces various disposable components, such as automated catheter advancement devices, and collaborates with Osypka AG to develop next-generation magnetic ablation catheters. Founded in 1990 and headquartered in St. Louis, Missouri, Stereotaxis holds over 100 patents and markets its products through a combination of direct sales and partnerships with distributors and sales agents. The company's innovations aim to improve patient care through enhanced precision, safety, and efficiency in interventional procedures.

Leegur Oy develops real time adaptation software tools for mobile and fixed Internet services. The company also offers planning, implementation, and customer support services.

Direct Conversion is a company that specializes in the development of digital imaging tools tailored for medical, dental, and industrial applications. It focuses on creating, manufacturing, and supplying advanced photon counting and tomosynthesis-based 3D X-ray imaging sensors. These products are rooted in proprietary X-ray technologies, enabling the company to provide customized original equipment manufacturer (OEM) solutions and small area detection applications. Through its innovative approach, Direct Conversion aims to enhance imaging capabilities across various sectors, contributing to improved diagnostic and operational efficiencies.

Hybrigenics Pharma is a bio-pharmaceutical company specializing in researching and developing new targets and therapies for cancer treatment. Their focus lies in studying Deubiquitinating Enzymes (DUBs) and the potential of patented DUB inhibitors in combating different cancer indications. Notably, the company has ceased the development of inecalcitol, a vitamin D receptor agonist.

Coley Pharmaceutical Group operates as a biopharmaceutical company developing therapeutics and drug candidates that direct the human immune system to fight cancers, asthma and allergy, autoimmune disorders, and to enhance the effectiveness of vaccines. The company was formerly known as CpG ImmunoPharmaceuticals, Inc. and in August 2000 it changed its name to Coley Pharmaceutical Group, Inc. The company was founded in 1997 and is based in Wellesley, Massachusetts. As of December 28, 2007, Coley Pharmaceutical Group, Inc. operates as a subsidiary of Pfizer Inc.